Pham Quang X 4
4 · Cadrenal Therapeutics, Inc. · Filed May 29, 2026
Research Summary
AI-generated summary of this filing
Cadrenal Therapeutics (CVKD) 10% Owner Pham Quang Sells Shares
What Happened Quang Pham, a 10% owner of Cadrenal Therapeutics (CVKD), reported three open‑market sales (code S) executed in May 2026 totaling 12,763 shares for aggregate proceeds of approximately $69,451. The sales were: 6,476 shares on 2026-05-11 at an average $5.76 ($37,302); 3,298 shares on 2026-05-12 at an average $5.28 ($17,413); and 2,989 shares on 2026-05-28 at an average $4.93 ($14,736). The May 11 sale was executed under a Rule 10b5-1 trading plan adopted September 25, 2025.
Key Details
- Transaction dates & reported averages:
- 2026-05-11: 6,476 shares @ $5.76 — $37,302 (footnote: price is a weighted average; individual trades ranged $5.47–$6.12).
- 2026-05-12: 3,298 shares @ $5.28 — $17,413 (weighted average; range $5.07–$5.535).
- 2026-05-28: 2,989 shares @ $4.93 — $14,736 (weighted average; range $4.81–$5.07).
- Total sold: 12,763 shares for ~$69,451.
- Ownership after transaction: the filing corrects a prior Form 4 understatement (see footnotes F3 and F6). The precise "owned after" figure is provided in the full Form 4.
- Notable footnotes: F1 confirms the May 11 sales were under a pre-established Rule 10b5-1 plan; F2/F4/F5 explain reported prices are weighted averages with ranges and that transaction-level detail is available on request; F7 notes Mr. Pham holds certain shares as Trustee of The PVBQ Living Trust and has sole voting/dispositive power for that trust.
- Timeliness: The filing on 2026-05-29 follows the transactions (earliest 2026-05-11) and the prior Form 4 filed 2026-05-26 was amended here — the record indicates late reporting relative to the typical 2-business-day Form 4 deadline.
Context These were disposals by a 10% owner and include trades executed under a pre‑arranged 10b5‑1 plan, which typically reflect scheduled sales rather than contemporaneous insider reactions. Sales are common and do not, by themselves, indicate company prospects; purchases generally carry more direct bullish signal for retail investors. For precise post‑trade holdings and the detailed breakdown of prices for each individual trade, consult the full Form 4 filing (Accession 0001213900-26-062862).
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-05-11$5.76/sh−6,476$37,302→ 188,448 total - Sale
Common Stock
[F1][F4][F3]2026-05-12$5.28/sh−3,298$17,413→ 185,150 total - Sale
Common Stock
[F1][F5]2026-05-28$4.93/sh−2,989$14,736→ 182,161 total
- 200,000(indirect: By Trust)
Common Stock
[F6][F7]
Footnotes (7)
- [F1]Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.47 through $6.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The total shares reported as directly owned in Column 5 takes into account subsequent transactions effected by the Reporting Person and reported on a Form 4 filed on May 26, 2026.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 through $5.535. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 through $5.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]On May 26, 2026, the Reporting Person filed a Form 4 which inadvertently understated in Column 5 the number of shares indirectly owned by the Reporting Person. This inadvertent understatement has been corrected in this filing.
- [F7]Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.